基于离散选择实验的肿瘤治疗偏好研究

Research on Cancer Treatment Preference Based on Discrete Choice Experiments

目的:系统评价国内外基于离散选择实验的肿瘤治疗偏好研究,为相关利益方提供参考。方法:基于PubMed、Embase、CNKI及万方数据库,检索2011年1月1日-2020年8月31日相关文献。针对纳入文献进行信息摘录、质量评价及结果分析。结果:共纳入52篇文献,主要来源于欧美国家,研究质量整体较为一般。有43项和21项研究分别关注了肿瘤患者和医疗服务提供者的治疗偏好。有50项研究设计了结果维度,40项研究设计了过程维度,18项研究设计了成本维度。从属性显著性评价及最重要属性评价结果来看,有效性、安全性和成本是关注重点;给药方式、等待时间和访视频率等也对患者偏好有影响。结论:全球肿瘤治疗偏好证据较为有限,研究质量有待提升。肿瘤患者和医疗服务提供者在治疗偏好选择方面整体考虑较为一致,但对治疗过程维度关注存在差异,基于我国肿瘤患者人群开展治疗偏好测量研究是将来工作开展的重要方向。

Objective: To systematically review the progress of research on cancer treatment preference based on discrete choice experiments(DCE) at home and abroad, so as to provide references for relevant stakeholders. Methods: Studies were identified based on PubMed, Embase, CNKI and Wanfang between January 1 st, 2011 and August 31 st, 2020. The information extract, quality evaluation and analysis of results were conducted for the included studies. Results: A total of 52 studies were identified and mainly from American and European countries. The overall quality was generally acceptable. 43 and 21 studies focused on the treatment preference of cancer patients and health care providers respectively. 50 studies designed the result dimension, and 40 studies designed the process and 18 studies designed cost dimensions. Effectiveness, safety and cost were the top priorities based on the significance of attributes and the most important attribute. The patients’ preferences were also associated with the mode of administration, waiting time and visit frequency. Conclusion: Global evidence on cancer treatment preference is limited and the quality of studies is needed to be improved. Overall, cancer patients and health care providers are consistent in treatment preference, and differences are observed in the dimension of treatment process. To carry out research on cancer treatment preference based on Chinese population is one of the most important direction in our future work.